PharmaVentures Limited is pleased to announce that it has been appointed to sell a former AstraZeneca manufacturing site in Avonmouth, near Bristol, England. The API plant was bought in 2016 by Avara Pharma Services who, as part of the deal, took over the drug substance manufacture of the high-cholesterol drug Crestor for AstraZeneca on a contract basis. Restructuring of the Avara group has resulted in the current decision to put the Avlon facility into Administration.
Bristol-based pharma firm Avara Avlon Pharmaceuticals has fallen into administration putting the jobs of all 270 of its staff at risk.
A CDMO that has made a habit of snapping up Big Pharma’s discarded manufacturing plants has put a former AstraZeneca plant into bankruptcy.
Avara Pharmaceutical Services has agreed to buy Novartis’ sterile manufacturing facility and development centre in Quebec, Canada.
Novartis has been looking to jettison some assets in its North American generics business, but as it turns out, it is a manufacturing facility in Canada that will be sold off first.
Avara Pharmaceutical Services, a world-class contract development and manufacturing organization (CDMO), today announced that the acquisition of the GlaxoSmithKline (GSK) consumer healthcare manufacturing facility in Aiken, South Carolina (USA) is complete.
Following the announced sale of AstraZeneca’s solid dose facility to Avara, the former outlines the Reims, France-based sites capabilities, and tells us why it is letting it go.
Avara Pharmaceutical Services will buy AstraZeneca’s secondary solid dosage form manufacturing, packaging and distribution facility in Reims, France.
In the last three months, budding CDMO Avara Pharmaceutical Services has bought three plants from Big Pharma. It bought a Pfizer sterile injectables facility in August, a GlaxoSmithKline consumer plant in September and has now picked up a solid dose facility from AstraZeneca to conclude an October deal.